Physician profile
David Khaski
NPI 1720268220
$11,453.48
in general payments reported to CMS, 2019-2025
32 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,760 · 2020: $641 · 2021: $4,200 · 2022: $1,975 · 2023: $958 · 2024: $677 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839 · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.98 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,002.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,348.44 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $947.31 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $859.94 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $809.13 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $641.78 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $639.05 | 2019-2025 | |
| Amgen INC. | $568.15 | 2019-2023 | Repatha |
| Lilly USA, LLC | $542.80 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Ge Healthcare | $340.00 | 2022 | |
| Abbott Laboratories | $281.06 | 2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $222.30 | 2019-2024 | |
| Heartflow, INC. | $218.24 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $173.32 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.84 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $102.97 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.88 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.00 | 2019-2021 | |
| Philips North America LLC | $67.77 | 2024-2025 | Mcot, (Ck4) Mcot |
| Alnylam Pharmaceuticals INC. | $60.64 | 2025 | Amvuttra |
| Teva Pharmaceuticals USA, INC. | $51.76 | 2021 | |
| Intra-Sana Laboratories | $45.17 | 2023-2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Corcept Therapeutics | $39.54 | 2024 | Korlym |
| Regeneron Healthcare Solutions, INC. | $37.42 | 2019-2021 | |
| Sanofi Pasteur INC. | $34.08 | 2020-2022 | |
| Boston Scientific Corporation | $30.46 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $23.45 | 2023 | Gemtesa |
| Alfasigma USA, INC. | $20.13 | 2021 | |
| Astellas Pharma US INC | $15.00 | 2020 | |
| Glaxosmithkline, LLC. | $14.79 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.00 | 2022 | |
| Cvrx, INC. | $10.78 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Khaski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.